• CSR Summary
• NCT00487539
• Primary Citation
• Data Specification

Approved Data Requests Associated with this Trial

• 2023-5534 : Quality tolerance limit and duplicated patient investigation in clinical trials
• 2023-5250 : Biomarkers for predicting long-term outcomes in ulcerative colitis
• 2023-5249 : Biomarkers for predicting long-term outcomes in ulcerative colitis
• 2023-5217 : Biomarkers for predicting long-term outcomes in ulcerative colitis
• 2023-5212 : Influence of Race and Ethnicity on the Efficacy of Biologic Drugs for Inflammatory Bowel Disease
• 2023-5195 : Predictive modeling of adverse events and symptoms patterns in large scale clinical trials
• 2023-5194 : Determining Endoscopic Treatment Response in Ulcerative Colitis and Crohn's Disease using the Win Probability Approach
• 2022-5120 : Validation of an artificial intelligence model on central read endoscopic disease severity in patients with ulcerative colitis
• 2022-5104 : Biomarkers for Predicting Long-term Outcomes in Ulcerative Colitis
• 2022-5013 : Identification of the Need for Hematopoietic Stem Cell Transplantation in Crohn's Disease Patients: A Ma-chine Learning Approach
• 2022-5012 : The Relationship between The Time to Achieve Clinical or Biomarker Remission and Long-term Outcomes in Inflammatory Bowel Disease
• 2022-4981 : Efficacy of medical therapies for ulcerative colitis according to disease distribution: An individual patient data meta-analysis of RCTs
• 2022-4975 : Impact of concomitant baseline medication on efficacy of biologics and small molecules for Inflammatory Bowel Disease
• 2022-4949 : Precision Medicine for Patients with Ulcerative Colitis Using Synthetic Controls
• 2021-4848 : Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative Colitis
• 2021-4829 : Placebo Rates in Inflammatory Bowel Disease: An Individual Patient Data Meta-analysis of Randomized Controlled Trials
• 2021-4698 : Early clinical response to biologics and small molecules for moderate-to-severe ulcerative colitis: a network meta-analysis
• 2020-4397 : Methods for Staging disease activity In ulcerative colitis; A comparison of endoscopy and Histology (MESIAH)
• 2020-4341 : Estimating the association between TNF inhibitors and Legionnaires' disease and Listeriosis: A Meta-analysis
• 2020-4318 : Enhancing inference from real-world data using externally-derived missing data models: a pilot study of Ulcerative Colitis
• 2019-4107 : Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: individual-patient level meta-analysis
• 2019-4092 : Cross-Trial Comparisons of Biologic Therapies for Auto-Immune Diseases
• 2018-3765 : Predictors of therapeutic and adverse effect outcomes of golimumab
• 2018-3737 : Gender-based Differences in Response to Therapy in Inflammatory Bowel Disease
• 2018-3556 : Influence of Race and Ethnicity on the Efficacy of Biologic Drugs for Inflammatory Bowel Disease
• 2018-3121 : Speed of onset of infliximab and golimumab in patients with moderate-severely active ulcerative colitis: A Post-Hoc Analysis of RCTs
• 2017-2306 : Continuing or Stopping 5-ASA in Biologic-Treated Patients with Moderate-Severe Ulcerative Colitis: A Post-Hoc Analysis of RCTs
• 2017-1856 : Impact of Age on Safety and Efficacy of Biologic Therapy for Inflammatory Bowel Disease
• 2017-1746 : Heterogeneity in relative treatment efficacy by age, sex, socioeconomic status and comorbidity
• 2015-0691 : Impact of Biologic Therapy on the Risk of Arterial and Venous Thromboembolic Events in Chronic Autoimmune Diseases: A Post-Hoc Analysis of RCTs
• 2015-0677 : Meta-analysis: Duration of inflammatory bowel disease and its impact on efficacy of biologic drugs
• 2015-0612 : Impact of Obesity on Disease Course and Response to Biologic Therapy in Inflammatory Bowel Disease: A Post-Hoc Analysis of RCTs
• 2015-0339 : Impact of the dose of immunomodulators on pharmacokinetics of biologics: Patient level meta-analysis of randomized controlled trials